Fairvalue-Calculator Fairvalue-Calculator
EN DE

Coya Therapeutics, Inc (COYA) Fair Value & Analysis

Healthcare · US · Market cap $115M

Price$5.39
Fair Value$8.25
Upside+53.1%
Quality95/100
Evidence: Low Range $6.19 – $10.32

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Coya Therapeutics, Inc (COYA) currently trades at $5.39, while our model-based Fair Value estimate is $8.25 — implying the stock looks roughly 53.1% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease. In addition, its pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exo…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

Frequently asked questions

Is Coya Therapeutics, Inc (COYA) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $8.25 versus a price of $5.39 — about +53% (undervalued). Model-based estimate, not financial advice.
What is the fair value of COYA?
Our 21-model fair value for Coya Therapeutics, Inc is $8.25 (as of Jun 24, 2026), built from audited fundamentals. The current price is $5.39.
What is the quality score of COYA?
Coya Therapeutics, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.